MAOB and Dyskinesia: Additionally, enhancement of levodopa frequency (38.2%; n=187) and usage of some additives, such as dopamine agonists (40.1%, n=196) and COMT or MAO-B inhibitors (41.5%, n=203) were also regularly employed; 44.6% (n=218) of participants would reduce levodopa dose and add its frequency for patients with peak-dose dyskinesia, whereas only 14.5% (n=71) of those surveyed would choose amantadine for such condition (Table 2).